Abstract
Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known.
Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with community-acquired pneumonia (CAP) was conducted. Pneumococcal serotype was established using a validated multiplex immunoassay (Bio-Plex; Bio-Rad, Hercules, CA, USA).
The overall incidence for hospitalised CAP and pneumococcal CAP was 79.9 (95% CI 76.6–83.3) and 23.4 (95% CI 21.6–25.3) per 100 000 population, respectively. A decline in CAP (incidence rate ratio (IRR) per year 0.96, 95% CI 0.94–0.99; p=0.016) and pneumococcal CAP (IRR per year 0.84, 95% CI 0.80–0.89; p<0.001) was observed over the 5-year period of the study. Between the pre- and post-PCV13 periods of the study, the incidence of CAP due to serotypes included in the PCV7 declined by 88% (IRR 0.12, 95% CI 0.08–0.20; p<0.001), and CAP due to the additional 6 serotypes in PCV13 declined by 30% (IRR 0.70, 95% CI 0.51–0.96; p=0.024).
Incidence of adult pneumococcal pneumonia declined over the last 5 years, with serotypes included in PCV13 declining post-PCV13 introduction, indicating early herd protection effects from PCV13 infant vaccination on adult non-bacteraemic disease. These effects may accrue over the coming years with implications for national pneumococcal vaccination policies in adults.
Abstract
This is the first study to indicate herd protection from infant PCV13 on adult non-bacteraemic pneumococcal pneumonia http://ow.ly/HHP75
Footnotes
Editorial comment in Eur Respir J 2015; 45: 1524–1525 [DOI: 10.1183/09031936.00064015].
This article has supplementary material available from erj.ersjournals.com
Support statement: This report is independent research arising from a Biomedical Research Fellowship supported by the National Institute for Health Research (NIHR), and an unrestricted investigator-initiated research grant from Wyeth (previously) and Pfizer. The study concept was developed and agreed by the authors with no input from the funding bodies. Pfizer (previously Wyeth), had no part in the design or execution of the study, the analysis and interpretation of the results, the writing of this manuscript or the decision to submit for publication. The data are the sole responsibility of the authors and the sponsor for the study was Nottingham University Hospitals NHS Trust. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National for Institute for Health Research or Public Health England. Funding information for this article has been deposited with FundRef.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received October 4, 2014.
- Accepted December 16, 2014.
- Copyright ©ERS 2015